title: Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities.
abstract: Co-stimulatory tumor necrosis factor receptors (TNFRs) can sculpt the responsiveness of T cells recognizing tumor-associated antigens. For this reason, agonist antibodies targeting CD137, CD357, CD134 and CD27 have received considerable attention for their therapeutic utility in enhancing anti-tumor immune responses, particularly in combination with other immuno-modulatory antibodies targeting co-inhibitory pathways in T cells. The design of therapeutic antibodies that optimally engage and activate co-stimulatory TNFRs presents an important challenge of how to promote effective anti-tumor immunity while avoiding serious immune-related adverse events. Here we review our current understanding of the expression, signaling and structural features of CD137, CD357, CD134 and CD27, and how this may inform the design of pharmacologically active immuno-modulatory antibodies targeting these receptors. This includes the integration of our emerging knowledge of the role of Fcγ receptors (FcγRs) in facilitating antibody-mediated receptor clustering and forward signaling, as well as promoting immune effector cell-mediated activities. Finally, we bring our current preclinical and clinical knowledge of co-stimulatory TNFR antibodies into the context of opportunities for next generation molecules with improved pharmacologic properties.
authors.forename: Jeremy D
authors.initials: JD
authors.lastname: Waight
authors.forename: Randi B
authors.initials: RB
authors.lastname: Gombos
authors.forename: Nicholas S
authors.initials: NS
authors.lastname: Wilson
mesh_terms: D000818:Animals; D015703:Antigens, CD / Q000235:genetics / Q000276:immunology; D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology; D000074322:Antineoplastic Agents, Immunological / Q000627:therapeutic use*; D005786:Gene Expression Regulation; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007167:Immunotherapy / Q000379:methods*; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology / Q000473:pathology; D017452:Receptors, IgG / Q000819:agonists / Q000235:genetics / Q000276:immunology*; D018124:Receptors, Tumor Necrosis Factor / Q000819:agonists / Q000235:genetics / Q000276:immunology*; D015398:Signal Transduction; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000473:pathology
chemical_list: D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000074322:Antineoplastic Agents, Immunological; D017452:Receptors, IgG; D018124:Receptors, Tumor Necrosis Factor
keywords: 4-1BB; CD134; CD137; CD27; CD357; FcγR; GITR; OX40; TNFR; TNFRSF; TRAF; antibodies; cancer; clinical trials; co-stimulation; human; immunotherapy; oncology